NeoGenomics, Inc.’s NEO share price has dipped by 10.05%, which has investors questioning if this is right time to buy.

Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that the company will present ...